Abstract：
Identifying the lymph node target volume in patients with node-negative sinonasal squamous cell carcinoma (SNSCC) crossing the midline poses a challenge. This study aims to address this.
We retrospectively reviewed clinically N0 patients with tumors crossing the midline who received elective neck irradiation (ENI) from two centers between 1999 and 2019. The main endpoint was regional relapse-free survival (RRFS).
We included 104 patients: 64 received bilateral ENI, and 40 received ipsilateral-only ENI (median follow-up time was 89.99 and 95.01 months, respectively). At 5 years, the RRFS rates were comparable (57.68% vs. 55.83%, p = 0.372), as were the contralateral RRFS (57.68% vs. 61.62%, p = 0.541). Five-year OS, LRFS, and DMFS showed no significant difference between two groups.
Our findings provide preliminary evidence suggesting the potential for avoiding contralateral ENI in SNSCC patients with midline crossing tumors who undergo ipsilateral ENI, covering at least level II. Validation through future prospective studies is necessary.
We retrospectively reviewed clinically N0 patients with tumors crossing the midline who received elective neck irradiation (ENI) from two centers between 1999 and 2019. The main endpoint was regional relapse-free survival (RRFS).
We included 104 patients: 64 received bilateral ENI, and 40 received ipsilateral-only ENI (median follow-up time was 89.99 and 95.01 months, respectively). At 5 years, the RRFS rates were comparable (57.68% vs. 55.83%, p = 0.372), as were the contralateral RRFS (57.68% vs. 61.62%, p = 0.541). Five-year OS, LRFS, and DMFS showed no significant difference between two groups.
Our findings provide preliminary evidence suggesting the potential for avoiding contralateral ENI in SNSCC patients with midline crossing tumors who undergo ipsilateral ENI, covering at least level II. Validation through future prospective studies is necessary.
摘要：
背景：确定跨越中线的淋巴结阴性的鼻窦鳞状细胞癌（SNSCC）患者的淋巴结靶体积是一个挑战。本研究旨在解决这个问题。
方法：我们回顾性回顾了1999年至2019年间从两个中心接受选择性颈部照射（ENI）的临床N0例肿瘤越过中线的患者。主要终点是区域无复发生存期（RRFS）。
结果：我们纳入了104例患者：64例接受了双侧ENI，40例接受同侧仅ENI（中位随访时间为89.99和95.01个月，分别)。在5年,RFS率具有可比性(57.68%与55.83%,p=0.372),对侧RFS也是如此(57.68%vs.61.62%，p=0.541)。五年操作系统，LRFS,两组间DMFS无明显差异。
结论：我们的研究结果提供了初步证据，表明SNSCC中线穿越肿瘤患者有可能避免对侧ENI，至少覆盖二级。通过未来的前瞻性研究进行验证是必要的。
方法：我们回顾性回顾了1999年至2019年间从两个中心接受选择性颈部照射（ENI）的临床N0例肿瘤越过中线的患者。主要终点是区域无复发生存期（RRFS）。
结果：我们纳入了104例患者：64例接受了双侧ENI，40例接受同侧仅ENI（中位随访时间为89.99和95.01个月，分别)。在5年,RFS率具有可比性(57.68%与55.83%,p=0.372),对侧RFS也是如此(57.68%vs.61.62%，p=0.541)。五年操作系统，LRFS,两组间DMFS无明显差异。
结论：我们的研究结果提供了初步证据，表明SNSCC中线穿越肿瘤患者有可能避免对侧ENI，至少覆盖二级。通过未来的前瞻性研究进行验证是必要的。
